Keros Therapeutics Inc. (KROS) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Keros Therapeutics Inc. (KROS)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

12.52

-0.30 (-2.34%)

At close: Jan 14, 2025, 3:59 PM

12.06

-3.67%

Pre-market Jan 15, 2025, 06:46 AM EST

undefined% (undefined)

Bid	12.06
Market Cap	507.15M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-5.22
PE Ratio (ttm)	-2.4
Forward PE	n/a
Analyst	Buy

Ask	12.8
Volume	1,011,524
Avg. Volume (20D)	975,000
Open	12.99
Previous Close	12.82
Day's Range	12.21 - 13.04
52-Week Range	12.21 - 73.00
Beta	undefined

About KROS

Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in pat...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Apr 8, 2020

Employees 160

Stock Exchange NASDAQ

Ticker Symbol KROS

Website https://www.kerostx.com

Analyst Forecast

According to 12 analyst ratings, the average rating for KROS stock is "Buy." The 12-month stock price forecast is $63, which is an increase of 403.19% from the latest price.

Buy 58.33%

Hold 33.33%

Sell 0.00%

Stock Forecasts

Why Price Moved

1 month ago · Source

-73.15%

Keros Therapeutics shares are trading lower after ... Unlock content with Pro Subscription

1 month ago · Source

+8.34%

Keros Therapeutics shares are trading higher. The stock may be moving on continued strength after Guggenheim maintained a Buy rating on the stock yesterday and raised its price target from $96 to $102.

News

4 weeks ago · seekingalpha.com

Keros Therapeutics: Trading At Essentially Cash Value, Target Of $23 Per Share

Keros Therapeutics' stock plummeted due to safety concerns in its Phase 2 TROPOS trial, but the risk-reward profile remains favorable for a rebound. The stock's enterprise value dropped drastically, n...

1 month ago · benzinga.com

Keros Therapeutics Loses 75% Value In A Single Session - Here's Why

On Thursday, Keros Therapeutics, Inc. KROS voluntarily halted dosing in the 3.0 mg/kg and 4.5 mg/kg treatment arms in the ongoing TROPOS trial Phase 2 trial of cibotercept (KER-012) in combination wit...

1 month ago · benzinga.com

Adobe, Keros Therapeutics, Lovesac And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

U.S. stock futures were lower this morning, with the Nasdaq futures falling around 50 points on Thursday.

1 month ago · reuters.com

Keros Therapeutics halts dosing of blood pressure treatment after safety review

Keros Therapeutics said on Thursday that it has voluntarily halted usage of its 3.0 milligram (mg) and 4.5 mg doses of its high blood pressure treatment in a mid-stage study based on a safety review.

1 month ago · benzinga.com

Keros Therapeutics' Licensing Deal With Takeda Aligns With Broader Opportunity For Elritercept: Analyst

On Tuesday, Takeda Pharmaceutical Company Limited TAK entered into an exclusive licensing agreement with Keros Therapeutics, Inc. KROS to further develop, manufacture and commercialize elritercept wo...

1 month ago · businesswire.com

Takeda Strengthens Oncology Pipeline with Elritercept through Licensing Agreement with Keros Therapeutics

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced that it has entered into an exclusive licensing agreement with Keros Therapeutics, Inc. (Nasdaq: KROS) to f...